Having insurance coverage alone doesn’t guarantee that people can afford or would be willing to pay continuously for chronic disease medications like Ozempic, a new, large-scale study finds.
Looking at insured patients with type 2 diabetes and heart failure, researchers found that people with higher prescription copayments were less likely to consistently take glucagon-like peptide-1 receptor agonists (GLP-1) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) — two classes of drugs that yield additional, long-term benefits compared with older treatments but are also costlier.
For example, people with high copayments, defined as over $50, were about 50% less likely to adhere to GLP-1 drugs such as Ozempic and Trulicity than those with low copayments, defined as less than $10, according to the study published in JAMA Network Open Thursday.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect